HIV-Related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab

We present a case of a patient with well-controlled human immunodeficiency virus (HIV) infection and refractory classical Hodgkin lymphoma (HL) treated with nivolumab as fifth-line treatment, who achieved complete response (CR) by positron emission tomography –computed tomography (PET/CT). To our knowledge, this is the second case report of a patient exhibiting nivolumab’s response, and first reported CR in the setting of HIV-associated HL (HIV-HL).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research

Related Links:

ConclusionAlthough ATC was superior to CVP, clinical outcomes (TTP, progression-free survival, and overall survival) were similar compared to BD chemotherapy for patients with grade 3A FL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion: While providing potential clinical benefit, CAR T cell therapy utilizes resources across the therapeutic spectrum, and increasing use of this therapeutic modality can create challenges in institutional resource capacity. Identifying these resources will allow for better care delivery and allocation of funds. Further refinement of CAR T cell products and improvements in CAR T cell-related toxicity management may permit safer delivery of this therapy and reduce costs per patient. Additional analysis of resource utilization among patients treated with commercial CAR T cell products, as well as comparison with alte...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Overuse, Costs, and Utilization of Health Services Source Type: research
Publication date: Available online 4 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rustain Morgan, Mark Perry, Jennifer Kwak, Alexandria Jensen, Manali KamdarAbstractIntroductionMantle cell lymphoma (MCL) is a rare subtype of non–Hodgkin lymphoma and requires both bone marrow biopsy and fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to correctly stage the disease at diagnosis. However, accurate identification of bone marrow involvement by lymphoma on FDG PET/CT scans has not been previously demonstrated. We hypothesized that a voxel-based analysis of...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma have been reported to be at high risk of primary treatment failure, this was not predicted by iPET+ results. Thus, the iPET result should not be used to guide changes in front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur study has shown that 90% of PTCL cases will be FDG avid. However, PET/CT was not predictive for PFS or OS at any point. The only predictive factor was the presence of lymphopenia.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Mantle cell lymphoma is a rare disease that requires bone marrow sampling for correct staging. However, the results of the present retrospective, multi-institutional, 20-patient study suggest that a fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography voxel-based threshold, with a sensitivity of 100% and specificity of 87.5%, might eliminate the need for bone marrow biopsy for some patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: CT Scan | Hematology | Leukemia | Lymphoma | Myeloma | PET Scan